Every Form 4 that Dogwood Therapeutics, Inc. (DWTX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow DWTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DWTX filings page.
Dogwood Therapeutics, Inc. director Abel De La Rosa received a grant of stock options, giving the right to buy 16,800 shares of common stock. The options have an exercise price of $1.50 per share and were awarded at no cost as equity compensation.
After this grant, De La Rosa holds stock options for 16,800 underlying shares directly. The options become exercisable starting on June 16, 2027 and expire on June 16, 2036, providing long-term potential ownership if exercised in the future.
Thomas John C reported acquisition or exercise transactions in this Form 4 filing.
Dogwood Therapeutics director Thomas John C received a grant of stock options giving him the right to buy 16,800 shares of common stock at $1.50 per share. These options expire on June 16, 2036 and are held directly, with 16,800 derivative securities reported following the grant. This is a compensation-related award rather than an open-market purchase or sale.
Dogwood Therapeutics director Richard James Whitley received a grant of stock options for 16,800 shares of Common Stock. The options carry an exercise price of $1.50 per share, become exercisable on June 16, 2027, and expire on June 16, 2036. Following this award, he holds 16,800 derivative securities directly.
Dogwood Therapeutics director David R. Keefer received a new stock option grant for 16,800 shares of common stock. The options have an exercise price of $1.50 per share, allowing him to buy shares at that price in the future. Following this grant, he holds 16,800 options directly. The options become exercisable starting June 16, 2027 and expire on June 16, 2036, making this a long-term, compensation-related award rather than an open-market trade.
Grosswald Ralph reported acquisition or exercise transactions in this Form 4 filing.
Dogwood Therapeutics, Inc. reported that SVP of Operations Ralph Grosswald received a grant of stock options covering 82,500 shares of the company’s stock. These options were awarded as a form of equity compensation.
According to the disclosure, the option vests one-third on March 5, 2027, with the remaining portion vesting in equal 1/24th monthly installments thereafter, tying most of the award to continued service over time.
Dogwood Therapeutics, Inc. reported that its Chief Financial Officer, Angela Walsh, received a grant of stock options covering 82,500 shares on March 5, 2026. These options give her the right to buy company stock if and when she chooses to exercise them.
According to the filing, Walsh now holds 82,500 stock options following this award. The options vest over time, with one-third vesting on March 5, 2027 and the remaining amount vesting in equal 1/24th monthly installments thereafter, creating a multi‑year retention and incentive structure.
Dogwood Therapeutics, Inc. Chief Medical Officer Roger Michael Gendreau reported an equity compensation grant. He acquired a stock option covering 82,500 shares of Dogwood Therapeutics common stock at an exercise price of $0.00 per share.
The option was granted on March 5, 2026 and is held as a direct ownership interest. According to the disclosure, the option vests one-third on March 5, 2027, with the remaining two-thirds vesting in equal monthly installments over the following 24 months.
Duncan Gregory Scott reported acquisition or exercise transactions in this Form 4 filing.
Dogwood Therapeutics, Inc. reported that Chief Executive Officer and director Duncan Gregory Scott received a grant of stock options covering 330,000 shares on March 5, 2026. The options vest one‑third on March 5, 2027 and then in 1/24th monthly installments thereafter.
Dogwood Therapeutics, Inc. (DWTX) reported a major insider ownership change as CK Life Sciences–affiliated entities converted non-voting preferred stock into common shares. On November 21, 2025, each share of Series A and Series A-1 Non-Voting Convertible Preferred Stock automatically converted into 10,000 shares of common stock following stockholder approval of the conversion.
Sealbond Limited reported the conversion of preferred stock into 21,610,950 shares of common stock, with 21,822,333 common shares beneficially owned directly afterward. Conjoint Inc., another affiliate, reported the conversion of Series A-1 Preferred Stock into 2,842,638 common shares, held indirectly. CK Life Sciences Int'l., (Holdings) Inc. is listed as a director by deputization and 10% owner through its subsidiaries but disclaims beneficial ownership except for any pecuniary interest.